SCHEMBL4670544

SCHEMBL4670544

COc1ccc2cc(CN)ccc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.58
AKR1C3 P42330 1/20 0.58
AKR1C2 P52895 1/20 0.58
MAOB P27338 3/20 0.54
CYP1A2 P05177 2/20 0.54
KDM4E B2RXH2 1/20 0.54
NPC1 O15118 1/20 0.54
LMNA P02545 1/20 0.54
TP53 P04637 1/20 0.54
CYP3A4 P08684 1/20 0.54
MAPT P10636 1/20 0.54
MAOA P21397 1/20 0.54
SLC6A2 P23975 1/20 0.54
RAB9A P51151 1/20 0.54
SLC6A3 Q01959 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
PTGS2 P35354 1/20 0.54
CYP2A6 P11509 1/20 0.54
LOXL2 Q9Y4K0 1/20 0.51
RAD52 P43351 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31380296 1.00 PTGS1 (0.58) PTGS1AKR1C3AKR1C2MAOBCYP1A2
SCHEMBL6231623 0.96 CYP1A2 (0.55) PTGS1AKR1C3AKR1C2MAOBCYP1A2
SCHEMBL3716715 0.84 TAAR1 (0.68) PTGS1AKR1C3AKR1C2MAOBCYP1A2
Hydrochloric Acid SCHEMBL11267009 0.82 TAAR1 (0.66) PTGS1AKR1C3AKR1C2MAOBCYP1A2
SCHEMBL9016348 0.82 ASIC3 (0.57) CYP1A2CYP2A6LOXL2TAAR1
SCHEMBL6348328 0.82 KDM4E (0.48) MAOBCYP1A2KDM4ELMNACYP3A4
SCHEMBL9123911 0.81 TAAR1 (0.63) PTGS1AKR1C3AKR1C2MAOBCYP1A2
SCHEMBL2056268 0.81 AKR1C3 (0.59) PTGS1AKR1C3AKR1C2CYP1A2KDM4E
SCHEMBL15345375 0.80 NQO1 (0.48) AKR1C3AKR1C2CYP1A2NPC1LMNA
SCHEMBL4951818 0.80 MAOB (0.73) MAOBCYP1A2TP53CYP3A4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3344626-B9 THERAPEUTIC COMPOUNDS FOR PAIN AND SYNTHESIS THEREOF JANSSEN PHARMACEUTICA NV (BE) 2021-08-11 EP disclosed
EP-3344626-B1 THERAPEUTIC COMPOUNDS FOR PAIN AND SYNTHESIS THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-07-08 EP disclosed
WO-2017040767-A1 THERAPEUTIC COMPOUNDS FOR PAIN AND SYNTHESIS THEREOF JANSSEN PHARMACEUTICA NV (BE) 2017-03-09 WO disclosed
EP-2657214-B1 PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL MITSUBISHI GAS CHEMICAL CO (JP) 2017-02-15 EP disclosed
US-8993774-B2 Process for production of aromatic alcohol or heterocyclic aromatic alcohol MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2015-03-31 US disclosed
US-20130303775-A1 PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2013-11-14 US disclosed
EP-2657214-A1 PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL Mitsubishi Gas Chemical Company, Inc. (JP) 2013-10-30 EP disclosed
US-20090247488-A1 ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS CANNIZZARO CARINA 2009-10-01 US disclosed
US-20090247488-A1 ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS CANNIZZARO CARINA 2009-10-01 US disclosed
US-7432261-B2 Anti-inflammatory phosphonate compounds GILEAD SCIENCES, INC. (US) 2008-10-07 US disclosed
US-6703392-B2 OREXIN RECEPTOR ANTAGONISTS FOR OBESITY OR SLEEPING DISORDER TREATMENT ACTELION PHARMACEUTICALS LTD. (CH) 2004-03-09 US disclosed
US-20030176415-A1 1,2,3,4-tetrahydroisoquinoline derivatives IDORSIA PHARMACEUTICALS LTD (CH) 2003-09-18 US disclosed
US-6589970-B2 This invention provides novel compounds, pharmaceutical compositions and methods of treating thrombotic disorders in mammals, the compounds having the formula: WYETH 2003-07-08 US disclosed
US-20030045560-A1 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) WYETH 2003-03-06 US disclosed
EP-1274687-A1 1,2,3,4- TETRAHYDROISOQUINOLINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2003-01-15 EP disclosed
WO-2003000649-A1 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) WYETH (US) 2003-01-03 WO disclosed
WO-2001068609-A1 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2001-09-20 WO disclosed
EP-0775133-B1 NAPHTHALENE AMIDES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION MENARINI LAB (ES) 2001-05-30 EP disclosed
EP-0775133-A1 NAPHTHALENE AMIDES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION LABORATORIOS MENARINI S.A. (ES) 1997-05-28 EP disclosed
WO-1996004267-A1 NAPHTHALENE AMIDES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION LABORATORIOS MENARINI S.A. (ES) 1996-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176415-A1 1,2,3,4-tetrahydroisoquinoline derivatives HCRTR2, HCRTR1, NPY2R PTGS1 933/4885AKR1C3 723/4885AKR1C2 914/4885
US-20090247488-A1 ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS PHOSPHO1, TNF, PTGES PTGS1 6/4885AKR1C3 2248/4885AKR1C2 3110/4885
US-20030045560-A1 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) SERPINC1, F11, SERPINE1 PTGS1 679/4885AKR1C3 323/4885AKR1C2 474/4885
US-20130303775-A1 PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL ADH1C, ADH1A, ADH5 PTGS1 3390/4885AKR1C3 9/4885AKR1C2 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.